Key Points
- GSK insider Julie Brown purchased seven shares at GBX 1,803 each, for a total of approximately £126.21.
- GSK shares opened at GBX 1,770.50, down 0.3%, while analysts maintained a consensus “Hold” rating and an average target price of GBX 2,039.38.
- Recent positive developments include Japanese approval of a prefilled Shingrix vaccine presentation and GSK’s move to late-stage development for its experimental mRNA seasonal flu vaccine.
GSK plc (LON:GSK - Get Free Report) insider Julie Brown purchased 7 shares of the firm's stock in a transaction dated Wednesday, September 9th. The stock was purchased at an average cost of GBX 1,803 per share, for a total transaction of £126.21.
GSK Trading Down 0.3%
Shares of GSK stock opened at GBX 1,770.50 on Friday. The company has a market capitalization of £70.94 billion, a PE ratio of 15.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK plc has a 52-week low of GBX 1,455 and a 52-week high of GBX 2,282. The business's fifty day moving average is GBX 1,901.77 and its 200 day moving average is GBX 1,968.13. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.
GSK (LON:GSK - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities research analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 2,000 target price on shares of GSK in a research report on Wednesday, September 2nd. Royal Bank Of Canada restated a "sector perform" rating and issued a GBX 1,975 target price on shares of GSK in a report on Tuesday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of GBX 2,039.38.
Get Our Latest Report on GSK
Trending Headlines about GSK
Here are the key news stories impacting GSK this week:
- Positive Sentiment: Japan’s Ministry of Health approved a prefilled, ready-to-use presentation of GSK’s Shingrix shingles vaccine. The format could improve convenience for healthcare providers and support Shingrix adoption in an important market. Japan MHLW approves GSK prefilled Shingrix presentation
- Positive Sentiment: GSK is advancing its experimental mRNA seasonal flu vaccine into late-stage development after mid-stage results showed stronger immune responses than standard- and high-dose approved flu vaccines in younger and older adults. Success in late-stage trials could create a meaningful future growth opportunity, though clinical and regulatory risks remain. GSK mRNA flu vaccine development
- Neutral Sentiment: Several GSK executives acquired small amounts of stock under the company’s reward plan, including Julie Brown’s purchase of seven shares worth approximately £126. The transactions signal alignment with shareholders but are too small to represent a major investment signal. GSK executives acquire shares
- Neutral Sentiment: RBC reiterated its “Sector Perform” rating, indicating a balanced view rather than a strong bullish or bearish stance. Other brokerages have set an average target of about GBX 2,048.57, above the recent trading level. RBC reiterates GSK Sector Perform rating
- Negative Sentiment: Commentary highlighting that GSK trades below levels seen decades ago reflects continuing investor concerns about valuation, growth expectations and the company’s ability to overcome past challenges. This sentiment may be weighing on the shares despite the positive vaccine developments. Analysis of GSK share price
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
